With the market trading at record levels, it’s not so easy to find cheap stocks anymore. And by cheap we mean undervalued stocks with big upside potential ahead. Luckily TipRanks’ Top Analysts Stocks tool is here to help. With just a few clicks we can see the Street’s best-rated stock picks right now. Top recommended stocks are selected based on a TipRanks developed formula, factoring in ratings made by the best performing analysts.

And as for the cheap part- this tool also has that covered. By ordering the results by upside potential (see screenshot below), you can see which stocks have the most to climb. This upside potential means the difference between the current share price to the average analyst price target. As this is only based on ratings from the last three months, you can get a pretty good idea of each company’s outlook for the rest of 2018.

From the results, these 5 stocks really stood out. Let’s dive in now and take a closer look:

1. Iovance Biotherapeutics Inc (Nasdaq: IOVA)

This cutting-edge biotech is the only clinical-stage company advancing tumor infiltrating lymphocyte (TIL) technology. The company is conducting phase II clinical trials assessing TILs for multiple cancers including metastatic melanoma.

It also has five straight buy ratings and 37% upside potential from the current $17.70 share price. Chardan Capital’s Gbola Amusa (Profile & Recommendations) labels Iovance a ‘Top Pick for 2018’ explaining: “We reiterate our view on Iovance as a highly-differentiated company within the rapidly growing oncology-focused cell therapy sector”.

This five-star analyst adds “Positive clinical data for LN-144, coupled with the company’s robust and streamlined 22-day manufacturing process, leave the company poised for vast upside potential if 2018-2019 clinical catalysts play out”.

Indeed, his $30 price target indicates 69% upside potential from current levels. Bear in mind the stock has already surged 121% year-to-date.

View IOVA Price Target & Analyst Rating Details

2. Weight Watchers International (NYSE: WTW)

While the stock may have shed a few dollars in the last three months, its long-term outlook looks very appealing right now. “We look upon a recent pullback in WTW shares as largely mechanical in nature and at odds with strengthening fundamentals at the company” states top Oppenheimer analyst Brian Nagel (Profile & Recommendations). He has just initiated the stock with a ‘Buy’ rating and $98 price target (31% upside potential).

In fact, a significant transformation is now taking place at WTW. Under the leadership of new CEO Mindy Grossman, WTW is now tactfully introducing improved programming upon an enhanced digital infrastructure. As a result, WTW will be able to better connect with a larger and more diverse subscriber audience, explains Nagel.

And for investors, this new strategy spells a potentially “sustained, stronger and higher margin growth trajectory.” Indeed, WTW has picked up 8 buy ratings in the last 3 months vs just 1 hold rating. As you can see below, this is with a $114.14 average price target (52% upside potential).

View WTW Price Target & Analyst Rating Details

3. Dropbox Inc (Nasdaq: DBX)

Top DA Davidson analyst Rishi Jaluria (Profile & Recommendations) spies an ‘attractive buying opportunity’ over at Dropbox. Shares are now down over 10% in the last three months. The reason: departure of the company’s COO and a lock-up expiration.

However, Jaluria points out that recent software IPOs often bounce back quickly, and he anticipates no further selling from co-founders Drew Houston and Arash Ferdowsi. Plus the company is demonstrating impressive ‘underlying business momentum’, strong margins, innovative new features and ARPU growth.

As RBC Capital’s Mark Mahaney says: “We believe high expectations/multiples are warranted. Hence the upgrade…. We continue to view Dropbox as addressing a large TAM and view it as one of the clear market leaders”.

Overall the average analyst price target of $37 suggests big upside potential of 37%. This is with 5 buy ratings and just 1 hold rating in the last three months.

View DBX Price Target & Analyst Rating Details

4. Loxo Oncology (Nasdaq: LOXO)

Loxo Oncology is a clinical-stage biotech developing small molecule therapeutics for genetically defined cancers. What sets LOXO apart is that it first pinpoints areas of unmet need and then designs molecules that target disease causes.

Most notably, the company recently conducted a meeting with the FDA for LOXO-292 and expects to submit an NDA (new drug application) in late 2019. “LOXO-292 has established a best-in-class profile with blockbuster potential” exclaims top William Blair analyst Raju Prasad (Profile & Recommendations). The drug is designed for RET-rearranged cancers including non–small-cell lung cancer.

His excitement is based on impressive clinical results so far. “Overall, we believe that the robust activity observed within various patient subgroups, combined with a well-tolerated safety profile that showed no hypertension and proteinuria makes LOXO-292’s data best-in-class to date” explains Prasad.

Although he doesn’t have a price target on the stock, we can see that the average analyst price target suggests LOXO can climb 28% from current levels.

View LOXO Price Target & Analyst Rating Details

5. Marathon Petroleum (NYSE: MPC)

Ohio-based Marathon Petroleum owns seven refineries, all located in the Midwest US or on the US Gulf Coast. It also boasts a retail business, Speedway, which has over 2,700 retail locations in 23 states.

The big news right now is that Marathon is in the process of acquiring Andeavor, which would add nine refineries, logistics assets and additional retail stores, all located on the West Coast. Achieving a $1 billion synergy target would be a major catalyst for shares, says top RBC Capital analyst Brad Heffern (Profile & Recommendations).

And it’s not just the refining business that would benefit: “Marathon’s retail business, Speedway, is the most attractive retail franchise in our coverage universe, and the extension of the Speedway model to the acquired ANDV stores could provide meaningful upside” writes Heffern. He praises MPC for its diversified footprint and well-positioned midstream business.

View MPC Price Target & Analyst Rating Details